Update on ERbeta

Jan Ake Gustafsson; Anders Strom; Margaret Warner

doi:10.1016/j.jsbmb.2019.02.007

Update on ERbeta

Jan Ake Gustafsson, Anders Strom, Margaret Warner

Research output: Contribution to journal › Review article › peer-review

31 Scopus citations

Abstract

ERbeta (ERβ)celebrated its 20th birthday in 2016 and although the overwhelming data in the literature indicate a role for this receptor in the control of epithelial proliferation, neurodegeneration and immune function, no ERβ agonists have yet made it to the clinics. This is the situation, despite the fact that very good safe ERβ agonists have been synthesized and at least one has been donated to the NIH for distribution to researchers, who want to study its possible clinical use. Clinical trials are ongoing for the use of ERβ agonists in prostate cancer and schizophrenia but even today reviewers of our grants still make comments like “The grant is excellent except that the focus of the grant is ERβ”. There are multiple reasons for the non-acceptance of the value of ERβ and in this paper we will discuss issues raised by labs which do not support a role for ERβ in physiology or pathology.

Original language	English (US)
Article number	105312
Journal	Journal of Steroid Biochemistry and Molecular Biology
Volume	191
DOIs	https://doi.org/10.1016/j.jsbmb.2019.02.007
State	Published - Jul 2019

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Molecular Medicine
Molecular Biology
Endocrinology
Clinical Biochemistry
Cell Biology

Access to Document

10.1016/j.jsbmb.2019.02.007

Cite this

@article{64e2fa6e41fa4e9abdbb711e60c05076,

title = "Update on ERbeta",

abstract = "ERbeta (ERβ)celebrated its 20th birthday in 2016 and although the overwhelming data in the literature indicate a role for this receptor in the control of epithelial proliferation, neurodegeneration and immune function, no ERβ agonists have yet made it to the clinics. This is the situation, despite the fact that very good safe ERβ agonists have been synthesized and at least one has been donated to the NIH for distribution to researchers, who want to study its possible clinical use. Clinical trials are ongoing for the use of ERβ agonists in prostate cancer and schizophrenia but even today reviewers of our grants still make comments like “The grant is excellent except that the focus of the grant is ERβ”. There are multiple reasons for the non-acceptance of the value of ERβ and in this paper we will discuss issues raised by labs which do not support a role for ERβ in physiology or pathology.",

author = "Gustafsson, {Jan Ake} and Anders Strom and Margaret Warner",

year = "2019",

month = jul,

doi = "10.1016/j.jsbmb.2019.02.007",

language = "English (US)",

volume = "191",

journal = "Journal of Steroid Biochemistry and Molecular Biology",

issn = "0960-0760",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Update on ERbeta

AU - Gustafsson, Jan Ake

AU - Strom, Anders

AU - Warner, Margaret

PY - 2019/7

Y1 - 2019/7

N2 - ERbeta (ERβ)celebrated its 20th birthday in 2016 and although the overwhelming data in the literature indicate a role for this receptor in the control of epithelial proliferation, neurodegeneration and immune function, no ERβ agonists have yet made it to the clinics. This is the situation, despite the fact that very good safe ERβ agonists have been synthesized and at least one has been donated to the NIH for distribution to researchers, who want to study its possible clinical use. Clinical trials are ongoing for the use of ERβ agonists in prostate cancer and schizophrenia but even today reviewers of our grants still make comments like “The grant is excellent except that the focus of the grant is ERβ”. There are multiple reasons for the non-acceptance of the value of ERβ and in this paper we will discuss issues raised by labs which do not support a role for ERβ in physiology or pathology.

AB - ERbeta (ERβ)celebrated its 20th birthday in 2016 and although the overwhelming data in the literature indicate a role for this receptor in the control of epithelial proliferation, neurodegeneration and immune function, no ERβ agonists have yet made it to the clinics. This is the situation, despite the fact that very good safe ERβ agonists have been synthesized and at least one has been donated to the NIH for distribution to researchers, who want to study its possible clinical use. Clinical trials are ongoing for the use of ERβ agonists in prostate cancer and schizophrenia but even today reviewers of our grants still make comments like “The grant is excellent except that the focus of the grant is ERβ”. There are multiple reasons for the non-acceptance of the value of ERβ and in this paper we will discuss issues raised by labs which do not support a role for ERβ in physiology or pathology.

UR - http://www.scopus.com/inward/record.url?scp=85066102877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066102877&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2019.02.007

DO - 10.1016/j.jsbmb.2019.02.007

M3 - Review article

C2 - 30995525

AN - SCOPUS:85066102877

SN - 0960-0760

VL - 191

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

M1 - 105312

ER -

Update on ERbeta

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this